Atovaquone And Proguanil Hydrochloride Tablet, Film Coated
Product Images NDC 68001-245

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Atovaquone And Proguanil Hydrochloride (NDC 68001-245). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Atovaquone Chemical Structure (Ad25ab65 42aa 48f6 B5ed 247f3685d5bf 01)

Chemical structure diagram of the active ingredient Atovaquone, showing its molecular framework with a chlorophenyl group and quinone moiety.*

FDA Label Image

Proguanil HCl Chemical Structure (Ad25ab65 42aa 48f6 B5ed 247f3685d5bf 02)

Chemical structure of Atovaquone and Proguanil Hydrochloride showing the molecular arrangement of atoms with a chlorine-containing aromatic ring, multiple amine groups, and a hydrochloride component.*

FDA Label Image

Atovaquone And Proguanil HCl Tablets 250_100mg 100ct Label Rev 03/17 (Image 01)

Label for Atovaquone and Proguanil Hydrochloride Tablets, 250 mg / 100 mg, oral film-coated tablets. Manufactured by Glenmark Pharmaceuticals Ltd. for BluePoint Laboratories. The label includes dosage strength, barcode, and storage instructions, indicating a package size of 100 tablets.*

FDA Label Image

Atovaquone And Proguanil HCl Tablets 250_100mg 24 Unit Dose Tablets Carton Label Rev 02/17 (Image 02)

Packaging label for Atovaquone and Proguanil Hydrochloride Tablets 250 mg / 100 mg, film-coated oral tablets. The label shows the product name prominently with dosage strength, NDC 68001-245-15, and indicates 24 unit dose tablets (2 x 12). It is manufactured by Glenmark Pharmaceuticals Ltd., India, for BluePoint Laboratories. Storage instructions and usage notes are printed on the carton.*

FDA Label Image

Image 03

A dosage table for Atovaquone and Proguanil Hydrochloride showing pediatric dosing by weight categories (11-20 kg, 21-30 kg, 31-40 kg, and over 40 kg). The table lists total daily doses in mg for atovaquone and proguanil HCl, along with the corresponding dosage regimens in number of tablets per day, including pediatric and adult strengths.*

FDA Label Image

Image 04

Table showing dosage regimens for Atovaquone and Proguanil Hydrochloride in pediatric patients based on weight ranges. It lists total daily doses of atovaquone/proguanil HCl and specifies the number of pediatric or adult strength tablets to be taken daily for 3 consecutive days for acute malaria treatment.*

FDA Label Image

Image 05

Label for Atovaquone and Proguanil Hydrochloride Tablets, 250 mg / 100 mg strength, manufactured for BluePoint Laboratories by Glenmark Pharmaceuticals Ltd. The label indicates the product contains 100 tablets in a 100 cc jar, with storage instructions and a barcode. The label size is 105 mm by 45 mm.*

FDA Label Image

Image 06

Atovaquone and Proguanil Hydrochloride Tablets 250 mg/100 mg film-coated oral tablets packaging label. The label includes dosage strength, NDC 68001-245-15, and is labeled Rx Only. Packaged by BluePoint Laboratories with manufacturer Glenmark Pharmaceuticals Ltd. The full carton artwork shows storage instructions, dosage form, and unit dose packaging details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.